{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Raimundo AF"],"pubmed_abstract":["<h4>Introduction</h4>Diabetes is one of the major metabolic diseases worldwide. Despite being a complex systemic pathology, the aggregation and deposition of Islet Amyloid Polypeptide (IAPP), or amylin, is a recognized histopathological marker of the disease. Although IAPP proteotoxicity represents an important trigger of β-cell dysfunction and ultimately death, its exploitation as a therapeutic tool remains underdeveloped. The bioactivity of (poly)phenols towards inhibition of pathological protein aggregation is well known, however, most of the identified molecules have limited bioavailability.<h4>Methods</h4>Using a strategy combining in silico, cell-free and cell studies, we scrutinized a unique in-house collection of (poly)phenol metabolites predicted to appear in the human circulation"],"journal":["Frontiers in endocrinology"],"pagination":["1008418"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9797523"],"repository":["biostudies-literature"],"pubmed_title":["Urolithin B: Two-way attack on IAPP proteotoxicity with implications for diabetes."],"pmcid":["PMC9797523"],"pubmed_authors":["Dos Santos DJVA","Ferreira S","Menezes R","Brito JA","Raimundo AF","Saraiva N","Lopes-da-Silva M","Pobre V","Dos Santos CN"],"additional_accession":[]},"is_claimable":false,"name":"Urolithin B: Two-way attack on IAPP proteotoxicity with implications for diabetes.","description":"<h4>Introduction</h4>Diabetes is one of the major metabolic diseases worldwide. Despite being a complex systemic pathology, the aggregation and deposition of Islet Amyloid Polypeptide (IAPP), or amylin, is a recognized histopathological marker of the disease. Although IAPP proteotoxicity represents an important trigger of β-cell dysfunction and ultimately death, its exploitation as a therapeutic tool remains underdeveloped. The bioactivity of (poly)phenols towards inhibition of pathological protein aggregation is well known, however, most of the identified molecules have limited bioavailability.<h4>Methods</h4>Using a strategy combining in silico, cell-free and cell studies, we scrutinized a unique in-house collection of (poly)phenol metabolites predicted to appear in the human circulation","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-26T05:19:19.069Z","creation":"2025-02-19T01:57:12.027Z"},"accession":"S-EPMC9797523","cross_references":{"pubmed":["36589826"],"doi":["10.3389/fendo.2022.1008418"]}}